Development of a Non‐Coding‐RNA‐based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC-Reference-Cited by-同舟云学术

Development of a Non‐Coding‐RNA‐based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC

Published:2019-03-07 Issue:9 Volume:6 Page:1801885
ISSN:2198-3844
Container-title:Advanced Science
language:en
Short-container-title:Adv. Sci.

Author:

Guo Ruomi¹²^ORCID,Wu Zhiqiang¹³,Wang Jing¹⁴,Li Qingling¹²,Shen Shunli¹,Wang Weiwei¹⁵,Zhou Luyao¹⁴,Wang Wei¹⁴,Cao Zhong¹⁵,Guo Yu¹^ORCID

Affiliation:

1. Department of General SurgeryThe First Affiliated Hospital of Sun Yat‐Sen University Guangzhou 510080 China

2. Department of Radiology and VIP Medical CenterThe Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou 510630 China

3. Department of Radiation OncologyTianjin Medical University Cancer Institute & HospitalKey Laboratory of Cancer Prevention and TherapyNational Clinical Research Center for CancerTianjin's Clinical Research Center for Cancer Tianjin 300060 China

4. Department of Obstetrics and Gynecology and Medical UltrasonicsThe First Affiliated Hospital of Sun Yat‐Sen University Guangzhou 510080 China

5. School of Biomedical EngineeringSun Yat‐Sen University Guangzhou 510006 China

Funder

National Natural Science Foundation of China

Tianjin Science and Technology Committee

Guangdong Science and Technology Department

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.201801885

Reference48 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Management of hepatocellular carcinoma: An update

3. 1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY

4. Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation

5. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A quartet of cancer stem cell niches in hepatocellular carcinoma;Cytokine & Growth Factor Reviews;2024-10

2. WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities;Genes & Diseases;2024-03

3. Clinical impact of epithelial–mesenchymal transition for cancer therapy;Clinical and Translational Discovery;2024-01-28

4. Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy;Nanoscale;2024

5. Nanoscale Theranostics for Hepatocellular Carcinoma;Nanotheranostics for Diagnosis and Therapy;2024